I received a response from Sarah yesterday as well. My original question was:

"Thank you for guiding me to the January Corporate presentation for the most up to date information. However, I notice a discrepancy in the slides regarding the target number of events.

Slide 17 states "The study is an event-based trial and continues until 250 narrowly defined MACE events have occurred"

Slide 20 states "Trial completion – trial to continue until 250+ narrow MACE events have occurred"

Can you please clarify this discrepancy? Does reaching 250 events trigger the end of dosing, or does Resverlogix have the option to continue dosing past the 250 event mark?"

Along the lines of her response to RVXoldtimer, she wrote:

"Thanks for your question. Our plan is to start wrapping up the trial once we have reached 250 narrow MACE events. Due to the lag time in adjudication, we will likely end up with a number over this due to additional narrow MACE events we will likely see during this time."

BearDown